Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Empagliflozin in Healthy Egyptian Volunteers
NCT03059056Phase 1Completed
- Sponsor
- The British University in Egypt
- Start
- Feb 2017
- Primary completion
- Feb 2017
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of empagliflozin in type 2 diabetes mellitus (T2DM), sponsored by The British University in Egypt. Primary endpoints: Maximum Plasma Concentration at 12 hours, Time to Maximum Plasma Concentration at 12 hours and 1 more. Started Feb 2017; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03059056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03059056.